Esperion Therapeutics (ESPR) Misses Q2 EPS by 17c, provides guidance

Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $73.83 million versus the consensus estimate of $50.6 million.

The Company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• JPMorgan Starts Central Depository Services India Ltd (CDSL:IN) at Underweight
• JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight